General Announcement::Receives tentative ANDA approval for Dabigatran Etexilate Capsules 75 mg 110 mg & 150 mg

Issuer & Securities

Issuer/ Manager
GLENMARK PHARMACEUTICALS LIMITED
Securities
GLENMARK PH US$200M4.5%210802 - XS1456577334 - 4N4B
GLENMARK PHARM US$170M2%220628 - XS1426780125 - 4G8B
Stapled Security
No

Announcement Details

Announcement Title
General Announcement
Date &Time of Broadcast
19-Apr-2017 12:55:42
Status
New
Announcement Sub Title
Receives tentative ANDA approval for Dabigatran Etexilate Capsules 75 mg 110 mg & 150 mg
Announcement Reference
SG170419OTHRSIDX
Submitted By (Co./ Ind. Name)
Glenmark Pharmaceuticals LImited
Designation
Company Secretary & Compliance Officer
Effective Date and Time of the event
19/04/2017 17:00:00
Description (Please provide a detailed description of the event in the box below)
Sub:- Glenmark Pharmaceuticals receives tentative ANDA approval for Dabigatran Etexilate Capsules, 75 mg, 110 mg and 150 mg

With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.

Request you to kindly take the same on record.

Attachments

PRSING.pdf
Total size =725K